In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii

Journal of International Medical Research

Volumn 41, Issue 6, 2013, Pages 1830-1837

  Karaoglan, Ilkay ^a   Zer, Yasemin ^a   Bosnak, Vuslat Kecik ^a   Mete, Ayse Ozlem ^a   Namiduru, Mustafa ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Acinetobacter baumannii; cefoperazone sulbactam; colistin; combination therapy; eplisometer test; piperacillin tazobactam; synergistic effect; tigecycline

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFOPERAZONE; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; DISK DIFFUSION; DRUG EFFICACY; DRUG POTENTIATION; HOSPITAL INFECTION; IN VITRO STUDY; TEST STRIP;

ACINETOBACTER BAUMANNII; CEFOPERAZONE/SULBACTAM; COLISTIN; COMBINATION THERAPY; EPLISOMETER TEST; PIPERACILLIN/TAZOBACTAM; SYNERGISTIC EFFECT; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; CEFOPERAZONE; COLISTIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PENICILLANIC ACID; PIPERACILLIN; SULBACTAM;

EID: 84888230326     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513496172     Document Type: Article

References (34)

1. Kunz AN,Brook I.Emerging resistant gram-negative aerobic bacilli in hospital-acquired infections.Chemotherapy. 2010;56:492-500.
2. Cantòn R,Coque TM,Baquero F.Multi-resistant gram negative bacilli: from epidemics to endemics.Curr Opin Infect Dis. 2003;16:315-325.
3. Safdar N,Maki DG.The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile and Candida.Ann Intern Med. 2002;136:834-844.
4. Manchanda V,Sanchaita S,Singh NP.Multidrug resistant acinetobacter.J Glob Infect Dis. 2010;2:291-304.
5. Walsh TR.Emerging carbapenemases: a global perspective.Int J Antimicrob Agents. 2010;36:S8-S14.
6. Peleg AY,Seifert H,Paterson DL.Acinetobacter baumannii: emergence of a successful pathogen.Clin Microbiol Rev. 2008;21:538-582.
7. Gur D,Korten V,Unal S, et al.Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites.J Med Microbiol. 2008;57:1529-1532.
8. Carmeli Y,Akova M,Cornaglia G, et al.Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.Clin Microbiol Infect. 2010;16:102-111.
9. Suh B,Shapiro T,Jones R, et al.In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.Diagn Microbiol Infect Dis. 1995;21:111-114.
10. Wood CG,Hanes SD,Croce MA, et al.Comparison of ampicilin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia.Clin Infect Dis. 2002;34:1425-1430.
11. Fishbain J,Peleg AY.Treatment of Acinetobacter infections.Clin Infect Dis. 2010;51:79-84.
12. Urban C,Go E,Mariano N, et al.Effect of sulbactam on infections caused by imipenem resistant Acinetobacter calcoeticus biotype anitratus.J Infect Dis. 1993;167:448-451.
13. Levin AS.Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem.Clin Microbiol Infect. 2002;8:144-153.
14. Rose WE,Rybak MJ.Tigecycline: first of a new class of antimicrobial agents.Pharmacotherapy. 2006;26:1099-1110.
15. Gallagher JC,Rouse MH.Tigecyline fort the treatment of Acinetobacter infections: a case series.Ann Pharmacother. 2008;42:1188-1194.
16. Perez F,Hujer AM,Hujer KM, et al.Global challenge of multidrug-resistant Acinetobacter baumannii.Antimicrob Agents Chemother. 2007;51:3471-3484.
17. Principe L,D'Arezzo S,Capone A, et al.In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.Ann Clin Microbiol Antimicrob. 2009;8:18-18.
18. Jorgensen JH,Ferraro MJ.Antimicrobial susceptibility testing: A Review of General Principles and Contemporary Practices.Clin Infect Dis. 2009;49:1749-1755.
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement CLSI document M100-S19. Wayne, PA, USA, 2006.
20. Orhan G,Bayram A,Zer Y, et al.Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis.J Clin Microbiol. 2005;43:140-143.
21. Lolans K,Rice TW,Munoz-Price LS, et al.Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.Antimicrob Agents Chemother. 2006;50:2941-2945.
22. Navon-Venezia S,Leavitt A,Carmeli Y.High tigecyline resistance in multidrug-resistant Acinetobacter baumannii.J Antimicrob Chemother. 2007;59:772-774.
23. Li J,Nation RL,Owen RJ, et al.Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains.Clin Infect Dis. 2007;45:594-598.
24. Leclerc T,Perez JP,Debien B, et al.Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination.Ann Fr Anesth Reanim. 2007;26:1056-1058.
25. Taccone FS,Rodriguez-Villalobos H,De Backer D, et al.Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.Eur J Clin Microbiol Infect Dis. 2006;25:257-260.
26. Appleman MD,Belzberg H,Citron DM, et al.In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak.Antimicrob Agents Chemother. 2000;44:1035-1040.
27. Savov E,Chankova D,Vatcheva R.In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin.Int J Antimicrob Agents. 2002;20:390-392.
28. Rahal JJ,Urban C,Segal Maurer S.Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites.Clin Infect Dis. 2002;34:409-499.
29. Tan CH,Li J,Nation RL.Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.Antimicrob Agents Chemother. 2007;51:3413-3415.
30. Tripodi MF,Durante-Mangoni E,Fortunato R.Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination or in combination against epidemic multidrug resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.Int J Antimicrob Agents. 2007;30:537-540.
31. Wareham DW,Bean DC.In-vitro activity of polymyxin B in combinaton with imipenem, rifampicin and azithromycin versus mulidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases.Ann Clin Microbiol Antimicrob. 2006;21:10-10.
32. Foweraker JE, Laughton CR, Brown DF,et al.Comparison of methods to test antibiotic combinations against heterogenous population of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in Cystic Fibrosis. Antimicrob Agents Chemother 2009; 4809-4815.
33. Sopirrala MM, Mangino JE, Gebreyes WAet al.Synergy testing by Etest, microdilution checkerboerd, and time kill methods for pan drug resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 4678-4683.
34. Sands M,McCarter Y,Sanchez W.Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E test methodology.Eur J Clin Microbiol Infect Dis. 2007;26:521-522.